7-cyano-6-{[4-(tert-butyl)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine | 1354785-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-cyano-6-{[4-(tert-butyl)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine
• 英文别名: 6-[(4-tert-butylphenyl)sulfonyl]-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine-7-carbonitrile；6-(4-Tert-butylphenyl)sulfonyl-2-(trifluoromethyl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepine-7-carbonitrile
• CAS: 1354785-39-9
• 化学式: C₂₄H₂₁F₃N₄O₂S
• 分子量: 486.518
• InChiKey: WYRFVRAVXJIPMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  7-cyano-6-{[4-(tert-butyl)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine 在 羟胺 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 0.33h， 生成 6-[(4-tert-butylphenyl)sulfonyl]-N'-hydroxy-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine-7-carboximidamide
  参考文献：
  名称：

  Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

  摘要：

  Extensive structure activity relationship studies of a series derived from atropisomer 1, a previously described chiral benzocliazepine sulfonamide series, led to a potent, brain penetrant and selective compound with excellent preclinical pharmacokinetic across species. We also describe the utilization of a high throughput mouse pharmacodynamic assay which allowed for expedient assessment of pharmacokinetic and brain distribution.

  DOI：

  10.1021/ml200304j
• 作为产物：
  描述：

  3-氯邻苯二胺 在 2-双环己基膦-2',6'-二甲氧基联苯 、 吡啶 、 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙二醇单丁醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.33h， 生成 7-cyano-6-{[4-(tert-butyl)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine
  参考文献：
  名称：

  Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

  摘要：

  Extensive structure activity relationship studies of a series derived from atropisomer 1, a previously described chiral benzocliazepine sulfonamide series, led to a potent, brain penetrant and selective compound with excellent preclinical pharmacokinetic across species. We also describe the utilization of a high throughput mouse pharmacodynamic assay which allowed for expedient assessment of pharmacokinetic and brain distribution.

  DOI：

  10.1021/ml200304j

文献信息

• SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS
  申请人：Baker Robert K.

  公开号：US20100317645A1

  公开（公告）日：2010-12-16

  Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代二氮杂环磺酰胺是人体炸弹素受体的配体，特别是人体炸弹素受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，如肥胖和糖尿病。
• SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2102201B1

  公开（公告）日：2010-10-13
• US8153626B2
  申请人：——

  公开号：US8153626B2

  公开（公告）日：2012-04-10
• Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity
  作者：Harry R. Chobanian、Yan Guo、Ping Liu、Marc Chioda、Thomas J. Lanza、Linda Chang、Theresa M. Kelly、Yanqing Kan、Oksana Palyha、Xiao-Ming Guan、Donald J. Marsh、Joseph M. Metzger、Judith N. Gorski、Kate Raustad、Sheng-Ping Wang、Alison M. Strack、Randy Miller、Jianmei Pang、Maria Madeira、Kathy Lyons、Jasminka Dragovic、Marc L. Reitman、Ravi P. Nargund、Linus S. Lin

  DOI：10.1021/ml200304j

  日期：2012.3.8

  Extensive structure activity relationship studies of a series derived from atropisomer 1, a previously described chiral benzocliazepine sulfonamide series, led to a potent, brain penetrant and selective compound with excellent preclinical pharmacokinetic across species. We also describe the utilization of a high throughput mouse pharmacodynamic assay which allowed for expedient assessment of pharmacokinetic and brain distribution.